Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Teriparatide transdermal - Zosano Pharma

Next Previous
X
Search
Drug Profile

Teriparatide transdermal - Zosano Pharma

Alternative Names: B104; B106; Teribone™ transdermal; TH 0229; ThPTH; ThPTH (1-34); ZP-PTH

Latest Information Update: 02 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ALZA Corporation
  • Developer Asahi Kasei; Zosano Pharma
  • Class Diagnostic agents; Osteoporosis therapies; Peptide hormones; Skin disorder therapies
  • Mechanism of Action Osteogenesis stimulants; Parathyroid hormone receptor type 1 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Postmenopausal osteoporosis

Highest Development Phases

  • Suspended Postmenopausal osteoporosis

Most Recent Events

  • 29 Mar 2016 Teriparatide transdermal - Zosano Pharma is available for licensing in World as of 29 Mar 2016. www.zosanopharma.com/
  • 29 Mar 2016 Suspended - Phase-I for Postmenopausal osteoporosis in Australia (Transdermal)
  • 28 Sep 2015 Eli Lilly terminates its licence for teriparatide transdermal Worldwide

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top